Grants / Department of Health and Human Services / Centers for Disease Control and Prevention - ERA

RFA-DP-22-002: Epidemiology of Lupus: Longitudinal Studies in Population-Based Cohorts

Closed Closed January 19, 2022 Opportunity RFA-DP-22-002 ☆ Save

This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2021.

• Award ceiling$900,000
• Award floor$870,000
• Total funding$26.4 million
• Expected awards6
• Cost sharingNot required
• Funding typeCooperative Agreement

Key dates

Who can apply

This opportunity was open to any type of organization.

Special Eligibility. For an application to be considered, the application must be responsive to these Special Eligibility Requirements. If your application is incomplete or non-responsive to the special eligibility requirements listed in this section, it will not enter into the review process. Component A: Epidemiology of Lupus Among the Adults Applicants must have access to an existing and established baseline cohort of lupus patients that has been followed for at least 5 years. The sample size of the cohort to be used for this study should include a minimum of 400 lupus participants. If an applicant requests a funding amount greater than the ceiling of $900,000 (Section II. Award Information) for either Component (A or B) as indicated in Section II of this NOFO, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirement. Component B: Epidemiology of Lupus in the Pediatric Population Applicants must have access to an existing and established baseline cohort of lupus patients that has been followed for at least 3 years. The sample size of the cohort to be used for this study should include a minimum of 400 lupus participants. If an applicant requests a funding amount greater than the ceiling of $900,000 (Section II. Award Information) for either Component (A or B) as indicated in Section II of this NOFO, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirement.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Past Chronic Diseases: Research, Control, and Prevention awards averaged $651,162; this notice allows up to $900,000 per award.
• Most of the program's money (35% over five years) went to nonprofits.
• No cost sharing or match is required.

What the grant funds

The primary purpose of this opportunity is to fund applicants with existing access to adult lupus patient populations and can extend current knowledge over 12-17 years from baseline. A second component of this funding opportunity will focus on the pediatric lupus - to advance existing knowledge of lupus in pediatric populations using an existing cohort of lupus patients. Because lupus is a rare condition, it is efficient to obtain new information from existing relevant cohorts with lupus. The research objectives among both adult and pediatric populations are to: Examine the treatment (e.g., medications including opioid; type; appropriateness; etc.) of people with lupus. Determine health care access and gaps that people with lupus experience in addressing their varied health problems (e.g., general health problems as well as those for specific lupus outcomes, such as nephritis; transitions to adulthood). Determine longer term natural history (severity, chronic pain, progression, morbidity, mortality, disability and quality of life, work/ school/activity interference, etc.) of people with lupus, including assessing potential genetic factors. Examine other factors related to disparities in lupus outcomes (e.g., age, sex, and race/ethnic group). Examine lupus comorbidities.

Category: Health.

Applying now

This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.